Spleen-Targeted Glabridin-Loaded Nanoparticles Regulate Polarization of Monocyte/Macrophage (Mo /Mφ ) for the Treatment of Cerebral Ischemia-Reperfusion Injury

Adv Mater. 2022 Sep;34(39):e2204976. doi: 10.1002/adma.202204976. Epub 2022 Sep 1.

Abstract

During cerebral ischemia-reperfusion (I-R) injury, the infiltration of monocyte/macrophages (Mo /Mφ ) into the ischemic penumbra causes inflammatory damage but also regulates tissue repair in the penumbra. The regulation and balance of Mo /Mφ polarization is considered as a potential therapeutic target for treating cerebral I-R injury. Herein, these findings demonstrate that glabridin (Gla)-loaded nanoparticles (i.e., NPGla -5k) can effectively inhibit M1-polarization and enhance M2-polarization of Mo /Mφ . Positron emission tomography (PET) imaging shows that NPGla -5k can selectively accumulate in the spleen following intravenous injection. Spleen-targeted Cy5-NPGla -5k can co-localize with peripheral macrophages in the penumbra at 24 h after tail-vein injection. Interestingly, NPGla -5k treatment can reduce inflammatory damage, protect dying neurons, and improve nervous system function. The protective effect of spleen-targeted NPGla -5k against cerebral I-R injury in mice encourages an exploration of their use for clinical treatment of patients with cerebral I-R injury.

Keywords: Glabridin; ischemic stroke; macrophage; nanomedicine; positron emission tomography (PET); spleen.

MeSH terms

  • Animals
  • Isoflavones
  • Macrophages
  • Mice
  • Monocytes
  • Nanoparticles*
  • Phenols
  • Reperfusion Injury* / drug therapy
  • Spleen

Substances

  • Isoflavones
  • Phenols
  • glabridin